These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6105768)

  • 41. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
    Havemann U
    Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
    [No Abstract]   [Full Text] [Related]  

  • 42. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pituitary dopamine receptor.
    Labrie F; Di Paolo T; Raymond V; Ferland L; Beaulieu M
    Adv Biochem Psychopharmacol; 1980; 23():217-27. PubMed ID: 6104906
    [No Abstract]   [Full Text] [Related]  

  • 44. Relative potency of some neuroleptics as antagonists at dopamine-receptors in vivo compared with their reported ability to displace haloperidol binding in vitro [proceedings].
    Cox B; Ennis C; Foote G
    Br J Pharmacol; 1980 Jan; 68(1):172P. PubMed ID: 6101975
    [No Abstract]   [Full Text] [Related]  

  • 45. Neuroleptic CNS effects: acute and chronic studies.
    Bunney BS
    Psychopharmacol Bull; 1979 Jan; 15(1):57-8. PubMed ID: 33410
    [No Abstract]   [Full Text] [Related]  

  • 46. Dopamine-sensitive adenylate cyclase in the retina: a point of action for D-LSD.
    Spano PF; Kumakura K; Trabucchi M
    Adv Biochem Psychopharmacol; 1976; 15():357-65. PubMed ID: 799461
    [No Abstract]   [Full Text] [Related]  

  • 47. The effect of alpha, beta, and dopamine receptor-blocking agents on the stimulation of rat erythrocyte adenyl cyclase by dihydroxyphenethylamines and their beta-hydroxylated derivatives.
    Sheppard H; Burghardt CR
    Mol Pharmacol; 1971 Jan; 7(1):1-7. PubMed ID: 5552248
    [No Abstract]   [Full Text] [Related]  

  • 48. Vascular dopamine receptor as a model for other dopamine receptors.
    Goldberg LI
    Adv Biochem Psychopharmacol; 1978; 19():119-29. PubMed ID: 358776
    [No Abstract]   [Full Text] [Related]  

  • 49. Chemistry of dopamine receptors.
    Kebabian JW; Clement-Cormier YC; Petzold GL; Greengard P
    Adv Neurol; 1975; 9():1-11. PubMed ID: 238374
    [No Abstract]   [Full Text] [Related]  

  • 50. Adaptational phenomena in neuroleptic treatment.
    Nielsen IM; Christensen AV; Hyttel J
    Adv Biochem Psychopharmacol; 1978; 19():267-74. PubMed ID: 29449
    [No Abstract]   [Full Text] [Related]  

  • 51. Dopaminergic inhibition of adrenergic neurotransmission as a model for studies on dopamine receptor mechanisms.
    Steinsland OS; Hieble JP
    Science; 1978 Jan; 199(4327):443-5. PubMed ID: 22933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanism for selectively inhibiting the activation of cyclic nucleotide phosphodiesterase and adenylate cyclase by antipsychotic agents.
    Weiss B; Levin RM
    Adv Cyclic Nucleotide Res; 1978; 9():285-303. PubMed ID: 27079
    [No Abstract]   [Full Text] [Related]  

  • 53. [The receptor-binding profile of neuroleptic agents].
    Eneman M
    TVZ; 1990 Feb; (3):89-93. PubMed ID: 1969274
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of drugs and lesions on dopamine-stimulated adenylate cyclase: evidence for different classes of dopamine receptors.
    Katzman R; Makman MH; Ahn HS; Mishra RK; Gardner E
    Trans Am Neurol Assoc; 1977; 102():76-9. PubMed ID: 98893
    [No Abstract]   [Full Text] [Related]  

  • 55. Inhibition of dopamine-sensitive adenylate cyclase in rat basal ganglia and other hormone sensitive adenylate cyclase systems by neuroleptic drugs.
    Miller R
    Br J Pharmacol; 1975 Mar; 53(3):457P-458P. PubMed ID: 1137755
    [No Abstract]   [Full Text] [Related]  

  • 56. [Biochemical effects of neuroleptics].
    Petit M; Dollfus S
    Encephale; 1990; 16(2):71-98. PubMed ID: 1972057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biochemical and pharmacological studies on dopamine receptors.
    Woodruff GN
    Adv Biochem Psychopharmacol; 1978; 19():89-118. PubMed ID: 358789
    [No Abstract]   [Full Text] [Related]  

  • 58. Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans.
    Bøgesø KP
    J Med Chem; 1983 Jul; 26(7):935-47. PubMed ID: 6134833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system.
    Spano PF; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1978; 19():155-65. PubMed ID: 358777
    [No Abstract]   [Full Text] [Related]  

  • 60. Developments in the pharmacology and therapeutics of parkinsonism.
    Calne DB
    Ann Neurol; 1977 Feb; 1(2):111-9. PubMed ID: 18978
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.